Encapsulation of CpG-ODN could reduce tissue-wide inflammation and thus reduce local toxicity effects, while maintaining the anti-LAM immune activation so crucial to inhibit LAM nodule proliferation. The gene discussed is TSC2; the disease is lymphangioleiomyomatosis.